Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Second Label Expansion Indication
28 juil. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
21 mai 2015 16h05 HE
|
Otonomy, Inc.
Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067
Achieved statistical significance on...
Otonomy Appoints Eric Loumeau as General Counsel and Chief Compliance Officer
18 mai 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces FDA Acceptance of AuriPro(TM) New Drug Application
28 avr. 2015 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Presents AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference
27 avr. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients
20 avr. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
18 mars 2015 16h14 HE
|
Otonomy, Inc.
SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Corporate Update
12 mars 2015 08h00 HE
|
Otonomy, Inc.
SAN DIEGO, March 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Third Quarter 2014 Financial Results and Provides Corporate Update
12 nov. 2014 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...